NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/19/2025
Back to search
Official data from USPTO
ELATIVE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
06/20/2025
Trademark type
Word
Nice classes
5, 42
Filing date
01/20/2021
Registration date
03/29/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/29/2022
Last transaction
06/20/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
33
Owner location
FR
Examiner
HUDSON, TAMARA
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
GENFIT
Representatives
Brooks R. Bruneau FisherBroyles LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of liver diseasescholestatic diseasesmetabolic diseasescancer diseasesinflammatory diseasesautoimmune diseases and cancers; chemical preparations for medical or pharmaceutical usenamely for the prevention and treatment of liver diseasescholestatic diseasesmetabolic diseasescancer diseasesinflammatory diseasesautoimmune diseases and cancers; organic preparations for medical or pharmaceutical usenamely for the prevention and treatment of liver diseasescholestatic diseasesmetabolic diseasescancer diseasesinflammatory diseasesautoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use
Class 42
Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for othersin particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and developmentproviding informationresults and data relating to scientific or medical research and development of pharmaceutical productsvia an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services
Publications
History of USPTO decisions and trademark events.
29 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/12/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/23/2022
FIMP
FINAL DISPOSITION PROCESSED
08/23/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/29/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/08/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
03/29/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2022
PUBO
PUBLISHED FOR OPPOSITION
01/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
01/10/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/22/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/22/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/22/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/09/2021
ALIE
ASSIGNED TO LIE
12/09/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/06/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/06/2021
RFNT
REFUSAL PROCESSED BY IB
09/11/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/25/2021
RFRR
REFUSAL PROCESSED BY MPU
08/25/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/07/2021
CNRT
NON-FINAL ACTION WRITTEN
08/06/2021
DOCK
ASSIGNED TO EXAMINER
08/03/2021
MAFR
APPLICATION FILING RECEIPT MAILED
06/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/08/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
06/07/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/03/2021
Continuous trademark protection
Get notified about every new filing that threatens ELATIVE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.